Filtered By:
Source: Circulation
Condition: Thrombosis
Procedure: Coronary Angioplasty
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 16 results found since Jan 2013.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
